A Senate government funding bill aims to delay most of the new federal restrictions on hemp-derived cannabinoid products for one month, moving their implementation from November 12 to December 11, while leaving in place restrictions on certain cannabinoids that the cannabis plant cannot naturally produce.
The proposal appears in Section 2019 of the Senate’s Continuing Appropriations and Extensions Act, 2027, which would fund the federal government through December 11. Congress enacted the new hemp restrictions on November 12, 2025, with a one-year delayed effective date.
Public Law 119-37 amended the federal definition of hemp so that it excludes certain hemp-derived cannabinoid products containing cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant, naturally occurring cannabinoids that were synthesized or manufactured outside the plant, or more than 0.4 milligrams combined total per container of total tetrahydrocannabinols, including THCA, and other cannabinoids with similar effects.
Under the proposed Senate provision, the November 12 effective date would remain in place for products containing cannabinoids that are not capable of being naturally produced by Cannabis sativa L., while the other Section 781 changes would be delayed until December 11.
Critics Warn Delay Would Extend Youth Access
U.S. Sen. Ted Budd (R-North Carolina) recently called on senators to strip the amendment from the continuing resolution, arguing that intoxicating hemp products remain easy for children to obtain in convenience stores, gas stations and grocery stores.
“The packaging is unmistakably designed to appeal to children,” Budd said, pointing to products that mimic popular snack and candy brands. He also cited sharp increases in pediatric cannabis poisonings and hospitalizations while arguing Congress should let the November restrictions take effect.
A coalition of 35 attorneys general and chief legal officers made a similar case in an August 4 letter urging congressional leaders to reject any attempt to delay, repeal, suspend or weaken the 2025 hemp definition. The coalition warned that a delay could increase youth access and allow the return of unregulated intoxicating cannabis products. It also noted that under the current federal definition, an 8-ounce package of hemp-derived gummies could contain more than 675 milligrams of THC while remaining below the 0.3% dry-weight threshold.
Supporters of the extension argue Congress needs more time to develop a durable regulatory approach. U.S. Sen. Amy Klobuchar (D-Minnesota) said the additional month would give hemp farmers, brewers and small businesses more time to plan while lawmakers pursue a long-term solution. Klobuchar and Paul previously joined bipartisan efforts to delay implementation of the federal hemp changes, including the Hemp Planting Predictability Act, which sought a longer implementation period.
Texas has Already Tightened Restrictions
As previously reported by The Dallas Express, the Texas Department of State Health Services reinstated clarifications to the state’s controlled-substance schedules effective July 31 following a Texas Supreme Court ruling upholding the agency’s authority over the definition of tetrahydrocannabinols. DSHS said the restored language addresses the distinction between naturally occurring and manufactured tetrahydrocannabinols.
The state is also enforcing rules adopted March 31 that count THCA toward the total delta-9 THC amount and impose age-verification, labeling and other requirements on Texas hemp sellers.
Regulation vs. Prohibition: The Broader Debate
The federal debate also comes during broader disagreement over whether intoxicating hemp products should be prohibited outright or subjected to tighter regulation.
Extensive reporting by The Dallas Express has documented concerns about youth access and product safety while also examining arguments from hemp businesses, consumers and medical-cannabis advocates who favor age restrictions, testing, labeling and other safeguards rather than an outright prohibition.
In Texas, that distinction became particularly important after Gov. Greg Abbott vetoed Senate Bill 3 in June 2025. The legislation would have broadly prohibited consumable hemp products containing THC, but Abbott rejected the measure and called for lawmakers to pursue regulation instead. The Dallas Express reported that Abbott said Texans on both sides of the debate had raised serious concerns and urged lawmakers to work toward a solution.
Texas subsequently moved toward tighter regulation. As The Dallas Express reported, new state rules took effect March 31, 2026, including additional requirements for consumable hemp products.
Separately, the Texas Supreme Court previously upheld the state’s prohibition on manufacturing and processing consumable hemp products for smoking in Texas, while DSHS said properly manufactured products from outside Texas may still be distributed and sold if they meet applicable requirements.
The rules also established higher licensing fees, additional testing and labeling requirements and a minimum purchasing age of 21.
The hemp industry has argued that regulation, rather than outright prohibition, could address many of the concerns surrounding intoxicating products while preserving access for adults.
Industry Arguments, Fee Hikes, and Medical Access
During a July Texas Senate hearing, industry representatives disputed lawmakers’ characterization of the entire hemp market as dangerous and argued that compliant businesses should not be treated the same as companies selling mislabeled or poorly tested products.
The financial impact of regulation has also become part of the Texas debate. In January, The Dallas Express reported that DSHS proposed raising the annual registration fee for hemp retailers from $150 to $20,000 per location and the manufacturer license fee from $250 to $25,000 per facility. Small-business owners warned the proposed increases could drive smaller operators from the market, while the proposed rules also included age verification and other requirements intended to strengthen oversight.
The broader cannabis debate also includes medical access. Texas has expanded its Compassionate Use Program in recent years, although the program remains more limited than medical-cannabis programs in many other states.
The Dallas Express has reported on both the program’s expansion and the barriers some patients encounter in accessing it, including limited physician participation, availability and public awareness.
Industry experts interviewed by The Dallas Express argued that consumers could lose access to products they use for purposes such as sleep, focus and general wellness if restrictions become too broad.
A December 2025 Dallas Express report examining the future of Texas hemp presented a different potential outcome: an expanded medical-cannabis program could help absorb some demand if certain hemp products leave the market, while compliant hemp oils, gummies, lotions and beverages could remain available to adults through age-gated retail and direct-to-consumer sales.
This does not eliminate the public-health concerns. The CDC warns that cannabis edibles can cause poisoning, particularly in children who accidentally ingest them.
Broader Policy Questions and Federal Status
These concerns also raise a separate policy question: whether intoxicating hemp products should be prohibited or instead subjected to a tightly regulated legal framework involving age verification, potency limits, laboratory testing, accurate labeling and restrictions on marketing to minors.
The policy disagreement extends beyond hemp-derived THC. In May, The Dallas Express examined the contrast between Texas’ tightening restrictions on hemp-derived intoxicants and changes in federal marijuana policy, noting that Texas remains among the more restrictive states despite recent expansions to its medical-cannabis program. The report noted concerns that limited dispensary availability can make access difficult for eligible patients, particularly in rural areas.
The proposed federal delay is not yet law. The Senate passed the continuing resolution (H.R. 6500) early on August 8 by a 90-6 vote, keeping the one-month delay of most federal hemp restrictions intact after tabling Sen. Ted Budd’s amendment to strip it. The bill now moves to the House, which is in recess until the first week of September and previously approved a version without the hemp language. A final decision is expected in early to mid-September, before the September 30 funding deadline, once the House acts and the measure reach President Trump for signature. Until then, the original November 12, 2026, effective date remains in place.
